# EDGAR Filing Document

**Accession Number:** 0002075320
**File Stem:** 0001213900-25-094743
**Filing Date:** 2025-10
**Character Count:** 4420
**Document Hash:** 81825cc17a0fcd44545f5d82bd16335b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-094743.hdr.sgml**: 20251001

**ACCESSION NUMBER**: 0001213900-25-094743

**CONFORMED SUBMISSION TYPE**: C/A

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20251001

**DATE AS OF CHANGE**: 20251001

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Polaryx Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0002075320
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** WY
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** C/A
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 020-36323
- **FILM NUMBER:** 251365293

**BUSINESS ADDRESS:**
- **STREET 1:** 140 EAST RIDGEWOOD AVENUE
- **STREET 2:** SUITE 415, SOUTH TOWER
- **CITY:** PARAMUS
- **STATE:** NJ
- **ZIP:** 07652
- **BUSINESS PHONE:** 201-940-7236

**MAIL ADDRESS:**
- **STREET 1:** SOUTH TOWER, 140 E RIDGEWOOD AVENUE
- **STREET 2:** SUITE 415
- **CITY:** PARAMUS
- **STATE:** NJ
- **ZIP:** 07652

### Attached PDF Documents

**Attachment 1:** `formca.pdf`

_No text found in this document._

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM C

### UNDER THE SECURITIES ACT OF 1933

### Issuer Information

**Name of Issuer:** Polaryx Therapeutics, Inc.

**Legal Status:** Corporation

**Jurisdiction of Incorporation/Organization:** WY

**Date of Organization:** 08-22-2014

**Physical Address:** South Tower, 140 E Ridgewood Avenue, Paramus, NJ, 07652

**Issuer Website:** www.polaryx.com

**Is there a Co-Issuer?:** No

**Intermediary Name:** DEALMAKER SECURITIES LLC

**Intermediary CIK:** 0001872856

**Intermediary File Number:** 008-70756

**Intermediary CRD Number:** 000315324

### Offering Information

**Compensation to Intermediary:** DealMaker will receive an 8.5% cash commission on securities sold in the offering (inclusive of all payment processing, transaction, e-signature and AML fees). There is also a $2,000 monthly platform fee and a $16,500 setup fee payable to DealMaker.

**Financial Interest in Issuer:** None.

**Type of Security Offered:** Common Stock

**Number of Securities Offered:** 20704

**Price per Security:** $0.70

**Method for Determining Price:** 0.70

**Target Offering Amount:** $15,000.05

**Oversubscription Accepted:** Yes

**Oversubscription Allocation Type:** Other

**Description of Oversubscription:** At Issuer's discretion.

**Maximum Offering Amount:** $4,999,999.82

**Deadline to Reach Target Amount:** 03-31-2026

### Annual Report Disclosure Requirements

**Current Number of Employees:** 11.00

**Total Assets (Most Recent Fiscal Year):** $5,001,000.00

**Total Assets (Prior Fiscal Year):** $2,315,000.00

**Cash & Cash Equivalents (Most Recent Fiscal Year):** $4,621,000.00

**Cash & Cash Equivalents (Prior Fiscal Year):** $2,000.00

**Accounts Receivable (Most Recent Fiscal Year):** $0.00

**Accounts Receivable (Prior Fiscal Year):** $0.00

**Short-Term Debt (Most Recent Fiscal Year):** $0.00

**Short-Term Debt (Prior Fiscal Year):** $128,000.00

**Long-Term Debt (Most Recent Fiscal Year):** $0.00

**Long-Term Debt (Prior Fiscal Year):** $0.00

**Revenues/Sales (Most Recent Fiscal Year):** $0.00

**Revenues/Sales (Prior Fiscal Year):** $0.00

**Cost of Goods Sold (Most Recent Fiscal Year):** $0.00

**Cost of Goods Sold (Prior Fiscal Year):** $0.00

**Taxes Paid (Most Recent Fiscal Year):** $0.00

**Taxes Paid (Prior Fiscal Year):** $0.00

**Net Income (Most Recent Fiscal Year):** $-30,356,000.00

**Net Income (Prior Fiscal Year):** $-3,779,000.00

**Jurisdictions Offered:**

ALABAMA, ALASKA, ARIZONA, ARKANSAS, CALIFORNIA, COLORADO, CONNECTICUT, DELAWARE, FLORIDA, GEORGIA, HAWAII, IDAHO, ILLINOIS, INDIANA, IOWA, KANSAS, KENTUCKY, LOUISIANA, MAINE, MARYLAND, MASSACHUSETTS, MICHIGAN, MINNESOTA, MISSISSIPPI, MISSOURI, MONTANA, NEBRASKA, NEVADA, NEW HAMPSHIRE, NEW JERSEY, NEW MEXICO, NEW YORK, NORTH CAROLINA, NORTH DAKOTA, OHIO, OKLAHOMA, OREGON, PENNSYLVANIA, RHODE ISLAND, SOUTH CAROLINA, SOUTH DAKOTA, TENNESSEE, TEXAS, UTAH, VERMONT, VIRGINIA, WASHINGTON, WEST VIRGINIA, WISCONSIN, WYOMING, DISTRICT OF COLUMBIA, B5, GU, PR, 1V, VI

### Signatures

**Issuer:** Polaryx Therapeutics, Inc.

**Signature:** /s/ Alex Yang

**Title:** Chief Executive Officer

---

**Signature:** /s/ Alex Yang

**Title:** Chief Executive Officer

**Date:** 10-01-2025